News – Adragos Pharma https://adragos-pharma.com Your Global CDMO Tue, 07 Jul 2026 14:43:22 +0000 en-US hourly 1 https://wordpress.org/?v=7.0.3 https://adragos-pharma.com/wp-content/uploads/2024/04/cropped-Adragos-Pharma-Symbol-2024-32x32.png News – Adragos Pharma https://adragos-pharma.com 32 32 Adragos Pharma Appoints Kostas Rengis as Chief Executive Officer https://adragos-pharma.com/leadership-transition-at-adragos-pharma/ https://adragos-pharma.com/leadership-transition-at-adragos-pharma/#respond Mon, 04 May 2026 07:41:55 +0000 https://adragos-pharma.com/?p=25054 MUNICH, Germany – May 5th, 2026 – Adragos Pharma, a global contract development and manufacturing organization (CDMO), today announced the appointment of Konstantinos (Kostas) Rengis as its new Chief Executive officer, succeeding Dr. Andreas Raabe, who founded the company and has led it over the past six years.

Mr. Rengis brings extensive international leadership experience across pharmaceutical manufacturing, R&D and CDMO operations, with a strong track record in leading complex multi-site organizations across Europe, North America, Latin America and Asia. Most recently, he served as Group CEO of FAMAR, where he led a significant transformation of the business and accelerated operational and commercial performance.

“My focus at Adragos is to build on the strong foundations already in place and continue developing a reliable, high-performing organization for our customers, employees, partners and shareholders, working closely with the Board and leadership teams across the organization,” said Mr. Rengis. “This next phase will focus on operational execution, consistent delivery, integration of capabilities across the network, and the continued development of our manufacturing, R&D and commercial activities.”

Since its founding, Adragos has grown into a multinational CDMO operating across six sites in five countries, becoming an established partner in the pharmaceutical outsourcing market. Dr. Raabe will remain a shareholder of Adragos and continue to support the company while shifting his focus from daily operations toward investment activities and advisory support.

“I thank Andreas for his leadership in founding and building Adragos and for laying the groundwork for its next phase,” added Mr. Rengis.

The transition has been structured to ensure full continuity for customers, partners and employees, with a defined handover period to support the continued reliability of Adragos as a long-term partner to its stakeholders.

About Adragos Pharma

Adragos Pharma is a global CDMO headquartered in Munich, Germany, focused on the development and manufacturing of pharmaceutical products. The company operates an international network across Europe and Japan, with capabilities in sterile injectables and complex dosage forms. Adragos operates manufacturing sites in France, Germany, Switzerland, and Japan, as well as a development site in Greece, and is backed by FSN Capital and the Prange Family Office.

]]>
https://adragos-pharma.com/leadership-transition-at-adragos-pharma/feed/ 0
Adragos Pharma Kawagoe signs basic agreement with Towa Pharmaceutical for strategic collaboration to support stable supply of off-patent medicines https://adragos-pharma.com/adragos-pharma-kawagoe-signs-basic-agreement-with-towa-pharmaceutica/ https://adragos-pharma.com/adragos-pharma-kawagoe-signs-basic-agreement-with-towa-pharmaceutica/#respond Thu, 16 Apr 2026 04:00:00 +0000 https://adragos-pharma.com/?p=24747

April 15, 2026 Adragos Pharma Kawagoe K.K. (Headquarters: Kawagoe, Saitama; Representative Director and President: Masanori Kurogome) has signed a basic agreement with Towa Pharmaceutical Co., Ltd. (Headquarters: Kadoma, Osaka; President and CEO: Itsuro Yoshida) to establish a strategic collaboration aimed at ensuring the stable supply of off-patent pharmaceuticals. Under the agreement, Adragos Pharma will promote contract manufacturing utilizing the Kawagoe plant and secure production capacity to supply up to 1.5 billion tablets per year for Towa Pharmaceutical on a planned basis.

As the importance of ensuring a stable supply of off-patent medicines continues to grow in Japan, Adragos Pharma believes that pharmaceutical contract manufac-turers have an important role to play in supporting a more sustainable supply structure. Through this collaboration with Towa Pharmaceutical, the Company aims to contribute to the broader national effort to strengthen domestic manufacturing capacity, production resilience, and long-term supply stability.

Pictured: Dr. Andreas Raabe, Founder and CEO of Adragos Pharma, and Mr. Itsuro Yoshida, President and CEO of Towa Pharmaceutical Co., Ltd.

Production framework

Leveraging this partnership, Adragos Pharma will accelerate capital investment at the Kawagoe plant and expand annual solid-dosage capacity from the current 1.0 billion tablets to 2.5 billion tablets in stages. Of this total, capacity of approximately 1.5 billion tablets will be allocated to Towa Pharmaceutical. By sharing demand and supply forecasts, the two companies will work to ensure a stable supply of medicines.

Comments

· Masanori Kurogome, Representative Director, Adragos Pharma Kawagoe K. K. “Our collaboration with Towa Pharmaceutical represents an important partnership in supporting the stable supply of off-patent medicines. Through capital investment at our Kawagoe plant, we will further strengthen our production and quality assurance systems and, with qualityas our highest priority, contribute to a more stable domestic supply of medicines. At the same time, this partnership will support the continued en-hancement of our capabilities as a CDMO and our sustainable growth.”

· Dr. Andreas Raabe, Founder and CEO, Adragos Pharma “This agreement reflects the important role that specialized manufacturing partners can play in supporting the stable supply of medicines. By investing in our Kawagoe site and working closely with Towa Pharmaceutical, we aim to contribute to a stronger and more resilient supply framework for off-patent medicines in Japan.”

About Adragos Pharma

Adragos Pharma is a fast-growing global CDMO headquartered in Munich, Germany. Leveraging a network of seven manufacturing sites across Europe and Japan, we provide end-to-end pharmaceutical services from development through commercial manufacturing to support our clients. With advanced technical exper-tise and a customer-centric approach, we deliver high-quality, reliable solutions that meet the evolving needs of the pharmaceutical industry.

]]>
https://adragos-pharma.com/adragos-pharma-kawagoe-signs-basic-agreement-with-towa-pharmaceutica/feed/ 0
Adragos Pharma finalizes the acquisition of Commercial-Scale Sterile Fill-Finish Manufacturing Site at Maisons-Alfort, France, from Sanofi https://adragos-pharma.com/adragos-pharma-acquires-prefilled-syringes-facility-paris/ https://adragos-pharma.com/adragos-pharma-acquires-prefilled-syringes-facility-paris/#respond Wed, 01 Apr 2026 09:00:00 +0000 https://adragos-pharma.com/?p=24608 Munich, April 1, 2026 – Adragos Pharma, a global contract development and manufacturing organization (CDMO), today announced that it completed the acquisition of a commercial-scale sterile fill-finish facility in Maisons-Alfort, France, from Sanofi. The Maisons-Alfort site is one of Europe’s largest manufacturing facilities for sterile injectables, with industrial-scale capacity for pre-filled syringes (PFS), as well as liquid and lyophilized vials. 

The facility, located in the south-eastern suburbs of Paris is regularly audited by international health authorities, including ANSM (France), NMPA (China), MFDS (South Korea), and ANVISA (Brazil), and supports the global supply of critical injectable medicines. 

The Maisons-Alfort site employees are joining Adragos Pharma, bringing with them expertise in Sterile Manufacturing, ensuring full operational continuity while preserving the technical excellence built over the years. This complete talent integration represents a major strategic asset for the site’s future.

This site significantly expands Adragos’ sterile injectables network, adding high-volume pre-filled syringe manufacturing capabilities to its existing vial and ampoule filling operations in Jura, Switzerland, and Livron, France. The combined platform establishes Adragos as one of the leading sterile injectables CDMOs in Europe.  

Dr. Andreas Raabe, Founder and CEO of Adragos Pharma, commented: 

“Maisons-Alfort is a landmark acquisition for Adragos and a defining step in our growth journey. We are adding one of Europe’s leading sterile manufacturing sites to our network. Our ambition is clear: to invest, scale, and further develop the site into a top-tier fill-finish platform. This transaction is fully aligned with our strategy to secure and expand highly differentiated pharmaceutical manufacturing capacity in Europe.” 

Moritz Hafner, Partner at FSN Capital (investment advisor to FSN Capital VI), added:

“This acquisition is a significant step in our strategy to build Adragos into a leading player in the European pharmaceutical CDMO market. The Maisons-Alfort site is a strong strategic fit – it enhances Adragos’ sterile injectables capabilities and adds a highly experienced team that will further strengthen the Adragos platform. We are very proud of the trust that Sanofi places in Adragos to continue producing life-saving medicine. We look forward to the journey ahead with the Adragos management team as we continue to grow and serve the increasing customer demand for high-quality pharmaceutical products.”

Philippe Charreau, Head of Manufacturing & Supply Sanofi France: 

“For decades, Maisons-Alfort has been a cornerstone of sterile manufacturing for Sanofi’s most trusted products, built on deep expertise, advanced capabilities, and the unwavering commitment of its employees. We are confident that Adragos will carry forward the site’s tradition of operational excellence, leveraging the exceptional talent and experience of these teams to continue serving patients and write a successful new chapter for this site.” 

The exact terms of the transaction will not be disclosed.

About Adragos Pharma 

Adragos Pharma is a global CDMO headquartered in Munich, Germany, focused on the development and manufacturing of pharmaceutical products. The company is building a differentiated international network across Europe and Japan, with a strong focus on sterile injectables and complex dosage forms. Adragos operates manufacturing sites in France, Germany, Switzerland, and Japan, as well as a development site in Greece, and is backed by FSN Capital and the Prange Family Office.

Media inquiries: publicrelations@adragos-pharma.com 

]]>
https://adragos-pharma.com/adragos-pharma-acquires-prefilled-syringes-facility-paris/feed/ 0
Celebrating Three Years of Success at Kawagoe! https://adragos-pharma.com/celebrating-three-years-of-success-at-kawagoe/ https://adragos-pharma.com/celebrating-three-years-of-success-at-kawagoe/#respond Tue, 03 Mar 2026 08:57:17 +0000 https://adragos-pharma.com/?p=23891 It has been three years since our Kawagoe site became part of the Adragos family, and it is a milestone that fills me and our entire team with immense pride. This journey has been one of transformation, growth, and partnership. Looking back at where we started and seeing where we are today, I wanted to share some reflections on this journey from a time of uncertainty to becoming a flagship site within our global network.

A Time of Transition

To truly appreciate the journey, it’s important to remember the landscape before the acquisition. Our team was navigating a period of significant change, which brought both challenges and opportunities.

Before the acquisition, Kawagoe was going through transformation which included downsizing driven by our previous owner. Our legacy business of solid oral dosage manufacturing had already been transferred out of the site, and some team members were understandably uncertain about the future of the business. At the same time, we tried to see these changes as the last opportunity to secure Kawagoe’s long‑term business continuity, and the team was making a conscious effort to approach this period in a positive and proactive way.

There were several potential owners under consideration, and I felt it was a good outcome that Adragos was selected, as its culture seemed most closely aligned with our site and our site’s values. I also expected that joining a highly specialized CDMO group would allow us to utilize Kawagoe’s strengths. My hope was that we could provide a stable working environment for our team while receiving investment in equipment and people that would help the site take the next step in its development.

That hope quickly turned into reality. With Adragos, the philosophy for operations is that the local site develops and executes its own plans. While this certainly increases our level of responsibility, I strongly felt the benefit of having more freedom and flexibility to act quickly based on decisions made close to the production – and I thought, ‘this will be a very positive change for us.’

Investment in People and Know-How

Since joining the team, we have been receiving continuous investment in people and know‑how – for example, by dispatching digital experts to the site and giving us opportunities to participate in cross‑group projects. We also receive global sales and marketing support to win new projects. All these forms of support have helped drive Kawagoe’s growth. The initiatives and direction set by the group in the digital area have clearly accelerated digitalization at Kawagoe. As a result, we will be able to visualize quality and production data in near real time, which is helping us reduce issues such as defects and downtime, and to improve our safety, quality, and productivity indicators.

From New Acquisition to a Core Global Contributor

Three years on, Kawagoe is no longer a ‘new’ site. We are a fully integrated and core part of the global network, contributing not only to business targets but also to the group’s collective knowledge. Our experience and know‑how in successfully taking over assets from Big Pharma have also been shared within the group as best practices. Looking ahead, we would like to continue to be a ‘flagship plant’ that demonstrates how long‑term business growth and stable operations can be achieved together within the greater team, and in doing so, contribute to strengthening trust globally.

Looking Forward with Ambition

Our journey is far from over. We are excited and motivated to build on our success and play an even larger role in serving the healthcare needs of Japan. My ambition is not only to grow, but also to have our site contribute to improving the overall healthcare environment in Japan through strengthening partnerships. To achieve this, we plan to expand our solid dosage manufacturing capabilities as planned, and further reinforce Kawagoe’s role as a site that combines stable supply with high flexibility.

]]>
https://adragos-pharma.com/celebrating-three-years-of-success-at-kawagoe/feed/ 0
Adragos Pharma Announces Swissmedic Approval for State-of-the-Art Manufacturing Line https://adragos-pharma.com/adragos-pharma-announces-swissmedic-approval-for-state-of-the-art-manufacturing-line/ https://adragos-pharma.com/adragos-pharma-announces-swissmedic-approval-for-state-of-the-art-manufacturing-line/#respond Tue, 03 Feb 2026 08:34:27 +0000 https://adragos-pharma.com/?p=23595 Courroux, Switzerland – Wednesday, 21 January, 2026 Adragos Pharma, a leader in the CDMO industry, is pleased to announce it has received formal approval from the Swiss Agency for Therapeutic Products (Swissmedic) for their newly modernized sterile manufacturing suite, the Beta Line.

This critical milestone follows a comprehensive modernization program in 2024/2025 and a successful Swissmedic site inspection in October of 2025. The approval confirms that the Beta Line meets the highest standards of regulatory compliance and is ready for GMP operations.

The extensive upgrade was a significant undertaking focused on ensuring future-readiness and incorporating the most advanced manufacturing technology, including state-of-the-art Reduced Access Barrier Systems (RABS).

Highlights of the validation and modernization program include:

  • 300,000 person-hours of dedicated work
  • 150 completed validation activities
  • 250 distinct equipment calibrations
  • 350 updated Standard Operating Procedures (SOPs)

In addition to regulatory approval, the site’s enhanced capabilities and quality systems were validated during three separate customer audits, all of which yielded positive feedback.

The site is now completing the final Aseptic Process Simulations (APS) to formally demonstrate pristine aseptic control. Upon successful completion, the team will resume manufacturing commercial batches to serve its robust order book.


About Adragos Pharma
Adragos Pharma is an internationally operating contract development and manufacturing organization, headquartered in Munich, Germany. Its declared goal is to expand its existing production network through acquisitions in Europe, North America, and Japan, to attain a global-leading position, and to set new standards in customer service and data centricity. In its buy-and-build growth strategy, Adragos Pharma is supported by FSN Capital, a leading Scandinavian investment firm.

For more information, contact us at publicrelations@adragos-pharma.com

]]>
https://adragos-pharma.com/adragos-pharma-announces-swissmedic-approval-for-state-of-the-art-manufacturing-line/feed/ 0
Adragos Pharma Expands in Japan: Boosting Production & Trust https://adragos-pharma.com/adragos-pharma-expands-in-japan-boosting-production-trust/ https://adragos-pharma.com/adragos-pharma-expands-in-japan-boosting-production-trust/#respond Fri, 14 Mar 2025 12:13:27 +0000 https://adragos-pharma.com/?p=16338 We have been featured in Yakuji Nippo for its expansion in Japan and investment in the Kawagoe site to boost solid dosage production. The article highlights the company’s focus on quality, transparency, and its commitment to strengthening Japan’s pharmaceutical supply chain. Read the article’s summary here below.

Adragos Pharma is actively seeking to expand its presence in Japan, focusing significantly on enhancing its production capabilities at the Kawagoe site in Saitama Prefecture. Acquired from Sanofi in 2023, this facility is set to increase its solid dosage production capacity to one billion tablets, with plans to further scale to a two-billion-tablet system. This expansion is part of Adragos Pharma’s commitment to bolstering the pharmaceutical supply chain in Japan, aligning with the nation’s health ministry’s objectives for a stable supply of essential medicines. The company is collaborating with pharmaceutical manufacturers and distributors to achieve these ambitious goals.

Adragos Pharma’s operational strategy centers on high-quality standards and strong compliance, supported by a customer-centric approach that values transparent communication. Streamlined processes, especially in technology transfer, help build client trust through clear and timely updates. Henny adds, “Its employees’ dedication to success and ability to adapt to the new business model were key factors. It has been recognized by global headquarters as one of the company’s most successful transformations,” underscoring how people and process improvements drive Adragos Pharma’s continued success.

The commitment to quality remains a top priority for Adragos Pharma, as it strives to uphold global standards across its operations in the U.S., Europe, and Japan. Henny emphasizes, “Quality is absolutely non-negotiable and remains our highest priority.” Guided by a corporate culture that values excellence in quality practices, the company is well-prepared to deliver high-caliber pharmaceutical products. Additionally, Adragos Pharma is exploring broader opportunities in the biopharmaceutical sector, including biosimilars, and is considering investments in new technologies such as vial and pre-filled syringe filling equipment to expand its service offerings.

As a relatively new entrant in the Japanese market, Adragos Pharma is keen to establish strong ties with potential clients. By inviting stakeholders to visit the Kawagoe site, the company aims to provide insights into its operational framework and quality-driven culture. Through a transparent and dependable business model, Adragos Pharma seeks to make a positive impression, encouraging clients to consider it as a trusted manufacturing partner. This strategy is designed to secure a stronger foothold in the Japanese pharmaceutical sector and support the company’s continued global growth.

Read the full article from Yakuji Nippo: https://yakunet.yakuji.co.jp/index.php?PAGE=LOGIN&TARGET_ID=138544

]]>
https://adragos-pharma.com/adragos-pharma-expands-in-japan-boosting-production-trust/feed/ 0
Adragos Pharma Installs New Liquid Filling Line in Leipzig https://adragos-pharma.com/adragos-pharma-installs-new-liquid-filling-line-in-leipzig/ https://adragos-pharma.com/adragos-pharma-installs-new-liquid-filling-line-in-leipzig/#respond Thu, 06 Mar 2025 15:12:09 +0000 https://adragos-pharma.com/?p=16167 Leipzig, Germany – March 6th 2025

Adragos Pharma, a leading contract development and manufacturing organisation (CDMO), today announced the completion of a €4 million project to install and commission an advanced, cGMP-compliant liquid filling line and accompanying cartoning machine at its facility in Leipzig, Germany. The new capabilities will offer nearly ten times the production capacity at the site, enabling the company to meet rising demand while maintaining the highest standards of quality, efficiency, and compliance.
The new line has the capacity to fill up to 13 million bottles per annum in various formats to supply pharmaceutical, cosmetic, and healthcare supplement products. The installation project initially involved relocating two existing semi-solid commercial manufacturing lines at the site to new production areas, which have now been inspected and are fully operational. These lines provide flexible capabilities for the manufacturing and packaging of ointments, creams, and gels.
“This new flexible production line marks a key milestone in the development of our Leipzig site, expanding its capabilities and reinforcing our dedication to delivering state-of-the-art manufacturing solutions to our customers,” said Florian Prell, Site Head of Adragos Leipzig. “Adragos is committed to growing and investing in innovation, and we are looking forward to the opportunities and client partnerships that this project will create, as we continue to lead the industry in high-quality liquid dose form manufacturing.”
The 13,300-square metre facility in Leipzig was established in 1926 and specialises in manufacturing semi-solid and non-sterile liquid pharmaceuticals. Employing over 130 professionals, its services and expertise include galenical dose form development, pilot batch production through to commercial supply, advanced analytical method development, as well as worldwide raw material procurement and product quality assurance.


About Adragos Pharma
Adragos Pharma is an internationally operating contract development and manufacturing organization, headquartered in Munich, Germany. Its declared goal is to expand its existing production network through acquisitions in Europe, North America, and Japan, to attain a global-leading position, and to set new standards in customer service and data centricity. In its buy-and-build growth strategy, Adragos Pharma is supported by FSN Capital, a leading Scandinavian investment firm. The company currently operates five production sites in France, Germany, Norway, Switzerland, and Japan, as well as a development site in Greece.

For more information, contact us at publicrelations@adragos-pharma.com

]]>
https://adragos-pharma.com/adragos-pharma-installs-new-liquid-filling-line-in-leipzig/feed/ 0
Adragos Pharma Acquires Baccinex: Swiss Fill-Finish Expert https://adragos-pharma.com/adragos-pharma-acquires-baccinex-a-leading-swiss-sterile-fill-finish-expert/ https://adragos-pharma.com/adragos-pharma-acquires-baccinex-a-leading-swiss-sterile-fill-finish-expert/#respond Mon, 25 Nov 2024 09:55:21 +0000 https://adragos-pharma.com/?p=14638
  • Strengthens Adragos’ sterile manufacturing capabilities with specialized expertise in aseptic fill-finish and lyophilization. 
  • Marks the addition of Adragos’ 6th global manufacturing site, enhancing its ability to serve clinical and commercial pharmaceutical production needs worldwide. 

Munich / Courroux, November 25, 2024 – Adragos Pharma, a global pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Munich, Germany, has acquired Baccinex, a Swiss-based expert in aseptic fill-finish manufacturing. This acquisition significantly enhances Adragos’ sterile manufacturing capabilities and marks a pivotal step in the expansion of its global network. 

Baccinex, based in Courroux, Jura, Switzerland, brings over 20 years of experience in sterile fill-finish processes for both liquid and lyophilized vials. Operating from its EU-GMP and US FDA-certified facility, Baccinex specializes in clinical trial supplies and small-to-medium scale commercial production, offering world-class quality and reliability to its pharmaceutical clients. 

Dr. Ursula Bausch, founder and CEO of Baccinex, shared her perspective on the partnership: 

“Joining Adragos Pharma marks a new chapter for Baccinex. Our shared commitment to quality, innovation, and customer-centric solutions creates an exciting synergy that will enable us to deliver even greater value to our clients worldwide.” 

Dr. Andreas Raabe, founder and CEO of Adragos Pharma, commented: 

“The acquisition of Baccinex represents a significant milestone for Adragos. Baccinex’s proven expertise in sterile liquids and lyophilization, combined with its operational excellence, enhances our ability to provide integrated solutions from development through to commercial supply. This addition strengthens our position as a global partner of choice for high-quality pharmaceutical manufacturing.” 

Dr. Ursula Bausch will continue to lead Baccinex as CEO, ensuring continuity in operations and leveraging her extensive expertise in sterile manufacturing. She will also remain a shareholder in the company, reflecting her strong commitment to its continued success as part of Adragos. 

The acquisition of Baccinex aligns seamlessly with Adragos’ strategy to build a world-class manufacturing network that provides tailored solutions to meet the evolving needs of its customers. 

Pestalozzi Attorneys at Law acted as legal advisor to Adragos Pharma. Capitalmind Investec acted as M&A advisor, and Kellerhals Carrard acted as legal advisor to Dr. Ursula Bausch. 

Terms of the transaction remain undisclosed. 

About Adragos 

Adragos Pharma is a rapidly growing global CDMO headquartered in Munich, Germany. With a network of six sites across Europe and Japan, Adragos offers comprehensive pharmaceutical services, supporting clients from development through to commercial production. Committed to delivering high-quality, reliable solutions, Adragos combines technical expertise with a customer-centric approach to meet the evolving needs of the pharmaceutical industry. 

For more information, visit www.adragos-pharma.com  

About Baccinex 

Baccinex is a Swiss-based CDMO specializing in aseptic fill-finish services for liquid and lyophilized vials. With over 20 years of experience, Baccinex operates an EU-GMP and US FDA-certified facility in Courroux, Jura, Switzerland, delivering high-quality pharmaceutical solutions tailored to the unique needs of its clients. The company’s commitment to excellence and innovation has established it as a trusted partner in the pharmaceutical industry. 

For more information, visit www.baccinex.com 

Press contact Adragos Pharma 

publicrelations@adragos-pharma.com 

]]>
https://adragos-pharma.com/adragos-pharma-acquires-baccinex-a-leading-swiss-sterile-fill-finish-expert/feed/ 0
Project Future: New Production Line Launched at Livron Facility https://adragos-pharma.com/project-future-new-production-line-launched-at-livron-facility/ https://adragos-pharma.com/project-future-new-production-line-launched-at-livron-facility/#respond Thu, 07 Nov 2024 15:42:57 +0000 https://adragos-pharma.com/?p=12059 We are thrilled to announce the launch of our cutting-edge ampoule filling line at Adragos’ Livron facility in France, marking a transformative milestone in Project Future.

This new line is a major investment in enhancing production capacity and furthering our commitment to quality and compliance. This new line increases our production capacity to over 160 million ampoules per year, with flexible fill volumes ranging from 1ml to 20ml. This addition underscores our dedication to meeting rising demand while exceeding regulatory standards and client expectations.

In May, Adragos’ Board members visited Livron to see the nearly completed line and were impressed by the facility’s transformation and the team’s dedication. The line is now fully operational within our newly renovated main building, positioning Adragos to lead in high-quality ampoule manufacturing.

new filling line Livron

With this fourth filling line, we’ve expanded capacity by 30%, fully meeting the regulatory requirements.

This new line also directly benefits our clients, as our CCO, Marco Gorgas emphasized: “We are always attentive to our customers’ needs to better serve their patients. We recognized not only a regulatory demand in Annex 1 but also an urgent need for greater capacity, particularly for larger-volume ampoules. That’s why we installed this fourth line, allowing us to offer a capacity of over 160 million ampoules, including options up to 20ml, tailored to serve our clients’ evolving requirements.”

One of Project Future’s greatest achievements was navigating the structural challenges of our historic Livron site, which dates back to 1918.

Gael Le Saux, Site Head Livron facility

As Gaël Le Saux, Site Head of Livron, explained: “With the site’s origins dating back to 1918, structural constraints presented considerable challenges. However, the team adapted brilliantly, raising the roof and rebuilding key areas to fit the new cleanroom, all while keeping operations seamless. The management of this project’s complexity was truly exemplary.”

Today, November 7th, we celebrate the official inauguration of the new ampoule filling line at our Livron facility. This special event brings together Adragos’ executive team, the mayor of Livron-sur-Drôme, local journalists, and our dedicated employees who have been integral to this project’s success.

This celebration is a testament to our team’s hard work and dedication and marks a new chapter of growth, innovation, and excellence for Adragos. We look forward to the new achievements and client partnerships this line will enable and are excited about the bright future ahead.

]]>
https://adragos-pharma.com/project-future-new-production-line-launched-at-livron-facility/feed/ 0
Committing To Climate Action: We Join The Science Based Targets Initiative https://adragos-pharma.com/science-based-targets-initiative/ https://adragos-pharma.com/science-based-targets-initiative/#respond Wed, 23 Oct 2024 11:49:12 +0000 https://adragos-pharma.com/?p=13349 [Munich, October 22nd] – Adragos Pharma, a global Contract Development and Manufacturing Organization (CDMO), is proud to announce its participation in the Science Based Targets initiative (SBTi), marking a significant commitment to environmental sustainability and corporate responsibility in the fight against climate change.

As a leader in pharmaceutical development and manufacturing, we have always prioritized innovation and efficiency. By joining the SBTi, we are now aligning our operations with the imperative to reduce greenhouse gas (GHG) emissions in accordance with the latest climate science.

Understanding the SBTi 

The Science Based Targets initiative is a partnership between CDP, the United Nations Global Compact, the World Resources Institute (WRI), the World Wide Fund for Nature (WWF), and the We Mean Business Coalition. It is dedicated to driving ambitious corporate climate action through science-based target setting. Companies and financial institutions around the world rely on the SBTi to guide them in setting necessary GHG emissions reductions targets to prevent the worst effects of climate change.

Our Commitment 

By committing to the SBTi, Adragos commits to set long-term science-based targets to reach net-zero value chain GHG emissions by no later than 2050 in line with the SBTi Net-Zero Standard and submit it for SBTi validation within a maximum of 24 months. By committing to set a net-zero target, Adragos acknowledges that it joins the Race to Zero campaign. This commitment not only reflects our responsibility to the planet but also to our customers, employees, and shareholders who expect sustainability to be at the core of our operations.

Commenting on this milestone, our COO, Marco Gorgas, stated,

By joining the Science Based Targets initiative, Adragos is taking a decisive step forward, not merely committing to sustainability, but actively advocating for it. In the CDMO industry, we have a pivotal role in shaping sustainable practices. Our commitment extends beyond compliance; it is about setting a precedent that integrates environmental stewardship directly into our core business strategies, inspiring industry-wide change and ensuring a healthier planet for future generations.

Our Sustainable Future 

As we continue to expand our global footprint, embracing sustainability remains a cornerstone of our strategy. The commitment to the SBTi is part of a broader approach to ensure that our operations contribute positively to our environmental responsibilities. We are setting an example in the pharmaceutical industry by proving that business growth and environmental stewardship can go hand in hand.

A Call to Action 

Adragos participation in the SBTi is just the beginning of our renewed focus on environmental stewardship. Adragos calls on our partners, suppliers, and peers within the pharmaceutical industry to join us in this crucial initiative. Together, we can make a significant impact on our planet’s health and ensure a sustainable future for all.

]]>
https://adragos-pharma.com/science-based-targets-initiative/feed/ 0